GLP-1 diabetes drugs linked to altered smell, taste and possible fertility benefits
A new cohort study of 438,474 type‑2 diabetes patients treated with GLP‑1 agonists found a 38 % higher incidence of olfactory and gustatory disorders such as anosmia, parosmia and parageusia over a follow‑up of up to two years. The increase was statistically significant but the absolute risk remained low. Researchers from Hadassah Medical Center, Hebrew University of Jerusalem and the Israeli Defense Forces Medical Corps recommend closer monitoring of these side‑effects.
In a separate investigation presented by endocrinologist Pratibha Natesh in the United Kingdom, 24 weeks of GLP‑1 therapy in overweight men improved testosterone levels, sperm count, morphology and motility, suggesting a potential role for the drugs in treating male infertility. The findings are limited to men with high body‑mass index and require further confirmation.
Both studies highlight emerging benefits and risks of GLP‑1 medications, which are prescribed in millions of courses annually in the United States for diabetes and weight management.